Market Overview

Tricida Announces Hiring of Dawn Parsell as Senior Vice President of Clinical Development


Tricida, Inc. (NASDAQ:TCDA) today announced the hiring of Dawn Parsell,
Ph.D., as Senior Vice President of Clinical Development. Dr. Parsell
will lead Tricida's clinical development of TRC101 as the company
prepares to begin its VALOR-CKD confirmatory postmarketing trial and
submit a New Drug Application (NDA) under the U.S. Food and Drug
Administration's (FDA) Accelerated Approval Program.

"Dawn's extensive experience in all phases of clinical development and
regulatory affairs make her an ideal addition to Tricida's executive
team," said Gerrit Klaerner, Ph.D., Tricida's CEO, president and board
member. "As a consultant to Tricida since 2014, Dawn has been
instrumental in the preclinical and clinical development of, and
regulatory strategy for, TRC101. Dawn's focused efforts on TRC101
clinical development will be invaluable to ensuring our goal of
providing a first-in-class treatment to patients with CKD who suffer
from metabolic acidosis. We are very pleased to have Dawn join the
Tricida team."

Dr. Parsell has over 24 years of biotechnology and pharmaceutical
industry experience, where she has been involved in the successful
development and approval of nine FDA-approved drugs. She has served as
an independent regulatory consultant to the industry since 2001,
providing strategic and tactical clinical and regulatory support to her
clients, including assisting in the design and implementation of
Tricida's TRC101 development program. From 1994 to 2001, Dr. Parsell
worked at Connetics Corporation in discovery, clinical development and
regulatory affairs positions, most recently as Director of Regulatory
Affairs. Dr. Parsell received a B.S. in Biochemistry and Genetics/Cell
Biology with Distinction from the University of Minnesota, a Ph.D. in
Biology from the Massachusetts Institute of Technology and completed a
post-doctoral research fellowship at the Howard Hughes Medical Institute
at The University of Chicago.

"I share Tricida's passion to develop a drug that can potentially slow
the progression of CKD," said Dr. Parsell. "The growing evidence that
treating metabolic acidosis can make a difference in the lives of CKD
patients drives the urgency to develop a drug like TRC101. I am eager to
continue this important work and delighted to join the company at this
important time."

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of its product candidate, TRC101, a non-absorbed,
orally-administered polymer designed to treat metabolic acidosis in
patients with chronic kidney disease (CKD). Metabolic acidosis is a
condition commonly caused by CKD that is believed to accelerate the
progression of kidney deterioration. Tricida has successfully completed
a pivotal Phase 3, double-blind, placebo-controlled trial of TRC101 in
CKD patients with metabolic acidosis. The results of this Phase 3 trial
along with results from a successful double-blind, randomized,
placebo-controlled Phase 1/2 trial and an ongoing safety extension
trial, TRCA-301E, are intended to serve as the basis for the submission
of an NDA for TRC101 under the Accelerated Approval Program of the FDA.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including for
example, the ability of our drug candidate to provide benefit to
patients or to become a first-in-class drug for the treatment of
metabolic acidosis and our ability to submit an NDA for TRC101 under the
FDA's Accelerated Approval Program. Forward‐looking statements involve
known and unknown risks, uncertainties, assumptions and other factors
that may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward‐looking statements.
These risks and uncertainties include, among others, the cost, timing
and results of clinical trials and other studies; that many drug
candidates that have completed Phase 3 trials do not become approved
drugs; there can be no assurance that the FDA would approve an NDA under
the Accelerated Approval Program or at all, and even if approval for a
drug is obtained, there can be no assurance that it will be adopted in
the market or accepted as a benefit to patients and healthcare
providers; and that there will not be possible safety and efficacy
concerns. The forward-looking statements contained in this press release
reflect Tricida's current views with respect to future events, and
Tricida does not undertake and specifically disclaims any obligation to
update any forward-looking statements.

For more information, visit

View Comments and Join the Discussion!